Highlights of SABCS
Dr. Christy Russell (VP, US Medical Affairs at Exact Sciences) reviews new data presented at SABCS 2021 and their implications for clinical management of breast cancer patients. Included is an in-depth discussion of the latest data from the landmark RxPONDER trial.
RxPONDER Clinical Trial Key Findings1
At SABCS 2020, Kevin Kalinsky, MD presented early RxPONDER data.
- The majority of HR+, HER2-, N1 patients can be spared chemotherapy when decisions are guided with the Oncotype DX test
- Postmenopausal women with 1-3 positive nodes and Recurrence Score result 0-25 can forgo adjuvant chemotherapy regardless of clinical pathological parameters
- Premenopausal women with 1-3 positive nodes and Recurrence Score result 0-25 significantly benefit from chemotherapy
RxPONDER study results are expected to be practice-changing for N1 HR+, HER2-, early breast cancer patients